Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), specifically engineered as a 44\u2011amino\u2011acid sequence that corresponds to the N\u2011terminal portion of human GHRH with a trans\u20113\u2011hexenoyl group attached at the N\u2011terminus. This modification extends the peptide\u2019s half\u2011life in experimental systems and enhances binding affinity to the GHRH receptor. Researchers employ tesamorelin to probe the regulatory networks that govern pulsatile growth hormone (GH) secretion from the anterior pituitary. Because the peptide mimics endogenous GHRH, it serves as a selective tool to isolate receptor\u2011mediated signalling cascades without confounding cross\u2011reactivity with other hypothalamic factors.<\/p>\n
Laboratories utilise the compound in cell\u2011based assays, perfused pituitary models, and in vivo models to map downstream effectors such as insulin\u2011like growth factor 1 (IGF\u20111) and to dissect feedback loops that involve somatostatin. The peptide is supplied solely for laboratory research purposes; it is not manufactured or approved for human or veterinary use. Any handling must comply with local institutional biosafety and chemical hygiene regulations.<\/p>\n
Selecting a research grade supplier for tesamorelin is critical to obtaining reproducible and interpretable data. Research grade designations imply that the manufacturer adheres to rigorous in\u2011process controls, characterisation protocols, and documentation standards that are absent from non\u2011specialist sources. The following elements distinguish a qualified supplier:<\/p>\n
A dependable supplier confirms peptide identity and homogeneity through orthogonal analytical techniques. High\u2011performance liquid chromatography (HPLC) quantifies purity, typically reporting values \u226598 %, while electrospray ionisation mass spectrometry (ESI\u2011MS) or matrix\u2011assisted laser desorption\/ionisation (MALDI\u2011MS) validates the molecular weight within an acceptable mass error (e.g., \u00b11 Da). For tesamorelin, the expected monoisotopic mass is approximately 5135.8 g\/mol, and any batch\u2011to\u2011batch variability must be transparently reported.<\/p>\n
Every shipment from a research grade supplier includes a Certificate of Analysis (CoA) that details:<\/p>\n
The CoA guarantees batch traceability, enabling researchers to correlate experimental outcomes with a specific production lot and to requalify the material during long\u2011term studies.<\/p>\n
Research grade suppliers provide handling guidelines that reflect stress\u2011testing data. They advise on solvent compatibility, freeze\u2011thaw stability, and protection from light and moisture. Such guidance minimizes degradation artefacts that could confound dose\u2011response relationships in sensitive assays.<\/p>\n
To ensure that tesamorelin meets the demands of modern molecular endocrinology, laboratories should set minimum acceptance specifications. Reputable suppliers align with these criteria:<\/p>\n
HPLC purity is routinely specified at \u226598 % (area under the curve at 214 nm or 220 nm). However, purity alone does not account for counter\u2011ions, water, or residual synthesis by\u2011products. The peptide content\u2014typically expressed as a percentage of the total lyophilised mass\u2014should be documented. For tesamorelin acetate, for instance, the net peptide content often ranges between 75 % and 85 %, with the remainder comprised of acetate and bound water. Accurate total peptide content allows researchers to calculate the molar amount of active peptide used in reconstitution, an essential step for inter\u2011study consistency.<\/p>\n
Tesamorelin is most commonly supplied as the acetate salt, which offers favourable solubility in aqueous buffers at neutral pH. Suppliers should state the counter\u2011ion type and the average acid content, as these parameters affect the final peptide concentration in stock solutions. Researchers requiring a different salt form (e.g., trifluoroacetate) for particular solvent systems can request custom synthesis through advanced supplier programmes.<\/p>\n
Lyophilised tesamorelin is stable when stored at \u221220 \u00b0C or below in a desiccated environment. Upon receipt, vials should be equilibrated to ambient temperature before opening to prevent moisture condensation. Once reconstituted, the peptide solution should be aliquoted and stored at \u221280 \u00b0C to minimise proteolytic degradation and aggregation. Repeated freeze\u2011thaw cycles must be avoided; single\u2011use aliquoting is strongly recommended. Suppliers will specify a retest period based on real\u2011time and accelerated stability studies, often 12\u201324 months from the date of manufacture for the lyophilised form.<\/p>\n
For cell\u2011based or in vivo research models, low endotoxin levels are critical. Research grade tesamorelin is typically subjected to endotoxin testing (LAL assay), with acceptance limits \u22641 EU\/mg. Some suppliers also provide a Certificate of Sterility if aseptic processing has been performed, although most peptides are supplied non\u2011sterile and the end\u2011user must filter the reconstituted solution through a 0.2 \u00b5m membrane before use in sensitive biological systems.<\/p>\n
Tesamorelin\u2019s selective activation of the GHRH receptor makes it a versatile tool across several domains of preclinical investigation. The following examples illustrate current laboratory applications\u2014all conducted under controlled research conditions and never in human subjects.<\/p>\n
Investigators use tesamorelin in primary pituitary cell cultures and hypothalamic slice preparations to delineate GHRH\u2011dependent signalling pathways. By measuring GH release via ELISA or RIA, studies probe factors such as intracellular cAMP accumulation, calcium flux, and phosphorylation of CREB. Comparative experiments with somatostatin or ghrelin analogues help map the interplay between stimulatory and inhibitory inputs that shape ultradian GH pulses.<\/p>\n
In adipocyte cell lines and rodent models, tesamorelin is applied to examine how enhanced GH secretion influences lipolysis, adipokine profiles, and regional fat distribution. Research focuses on visceral adipose tissue reduction and the molecular mechanisms linking GHRH receptor activation to hormone\u2011sensitive lipase and perilipin expression. Such studies often incorporate IGF\u20111 measurement to distinguish direct GH effects from downstream IGF\u20111\u2011mediated actions.<\/p>\n
Tesamorelin\u2011driven GH secretion raises circulating and local IGF\u20111 levels, providing a physiological method to study IGF\u20111 receptor activation in muscle, bone, and liver. Laboratory models explore how this axis affects mitochondrial biogenesis, protein synthesis, and glucose homeostasis. These investigations are conducted in transgenic animals or ex vivo tissue assays, with careful controls to isolate peptide\u2011specific responses.<\/p>\n
Finally, tesamorelin is deployed in animal models of relative GH deficiency or altered somatotroph function. Researchers monitor endpoints such as body composition, bone mineral density, and cognitive performance in aging or surgically modified animals. The peptide\u2019s defined structure and receptor selectivity allow for cleaner interpretation of results compared to crude GHRH extracts or less specific secretagogues.<\/p>\n
Procurement of research grade tesamorelin follows a structured process designed to confirm the buyer\u2019s legitimate research intent and to ensure the peptide arrives in optimal condition. Below is a step\u2011by\u2011step guide typical of major international suppliers.<\/p>\n
To comply with international regulations and supplier policies, first\u2011time purchasers must provide evidence of affiliation with a recognised research institution, university, or pharmaceutical company. Acceptable credentials include a verifiable institutional email address, a copy of the organisation\u2019s operating licence, or a statement of research purpose on official letterhead. This step is not a regulatory hurdle; it is a safeguard that restricts distribution to authorised laboratories engaged in legitimate scientific investigation.<\/p>\n
When placing an order, researchers must indicate:<\/p>\n
Bespoke synthesis services may also offer amino\u2011acid composition analysis, peptide sequencing (Edman degradation or MS\/MS), or circular dichroism spectroscopy for secondary structure confirmation at an additional cost.<\/p>\n
Tesamorelin lyophilised powder is typically shipped at ambient temperature with a desiccant pack, as the peptide remains stable for transit durations of several days. However, for extended journeys or extreme climates, refrigerated cold packs may be included. Express courier (FedEx, DHL, UPS) is the norm, with shipments fully tracked and visible to the customer. Lead times vary from same\u2011day dispatch for in\u2011stock catalogue items to 2\u20134 weeks for custom synthesis batches. The supplier will advise on transit times and help the customer coordinate receipt so the material can be placed immediately in \u221220 \u00b0C storage upon arrival.<\/p>\n
Upon dispatch, the customer receives a digital copy of the CoA and, if requested, a formal quotation or proforma invoice to facilitate internal procurement processing. The supplier\u2019s technical support team remains available to address questions about reconstitution buffers, solubility challenges, or peptide storage. Reputable suppliers also maintain batch reserve samples for a defined period, allowing re\u2011testing should any discrepancy arise in the customer\u2019s laboratory.<\/p>\n
Research Use Only Note:<\/strong> This product is intended exclusively for in vitro laboratory research and experimental model studies. It is not manufactured, labelled, or approved for any diagnostic, therapeutic, veterinary, or human application. Purchasers must ensure that all handling complies with applicable national and institutional regulations governing research chemicals.<\/p>\n R\u00e9serv\u00e9 \u00e0 la recherche. Ne pas utiliser chez l'homme ni chez les animaux.<\/em><\/p>","protected":false},"excerpt":{"rendered":" Introduction to Tesamorelin for Research Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), specifically engineered as a 44\u2011amino\u2011acid sequence that corresponds to the N\u2011terminal portion of human GHRH with a trans\u20113\u2011hexenoyl group attached at the N\u2011terminus. This modification extends the peptide\u2019s half\u2011life in experimental systems and enhances binding affinity to the GHRH […]<\/p>\n","protected":false},"author":1,"featured_media":1695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"news_category":[],"class_list":["post-1694","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n